Ftse Mib
33.766,29
-0,06%
DAX
19.884,75
-0,57%
S&P 500
5.930,85
1,09%
NASDAQ
19.572,60
1,03%
Bitcoin
95.492,79
-1,76%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ TScan Therapeutics Inc (TCRX) TScan Therapeutics Inc (TCRX) Notizie

TScan Therapeutics Inc

TCRX
3,04
0,11 (3,75%)
21 Dic 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
10/12/202414:14EDGAR2Form 8-K - Current report
09/12/202423:45GLOBETScan Therapeutics to Present Updated Data from the Ongoing..
05/12/202414:00GLOBETScan Therapeutics Named a Top Place to Work by The Boston..
02/12/202413:00GLOBETScan Therapeutics to Host Virtual KOL Event to Discuss..
21/11/202414:05EDGAR2Form 8-K - Current report
14/11/202422:05EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
12/11/202413:00GLOBETScan Therapeutics Reports Third Quarter 2024 Financial..
08/11/202420:17EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
05/11/202415:15GLOBETScan Therapeutics Announces Upcoming Oral Presentation of..
01/11/202412:00EDGAR2Form 8-K - Current report
04/10/202415:05GLOBETScan Therapeutics Announces Upcoming Presentations at the..
29/8/202413:00GLOBETScan Therapeutics to Participate in Upcoming Investor..
12/8/202413:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/8/202413:15EDGAR2Form 8-K - Current report
12/8/202413:00GLOBETScan Therapeutics Reports Second Quarter 2024 Financial..
14/6/202422:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202422:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202422:05EDGAR2Form S-8 - Securities to be offered to employees in employee..
14/6/202413:15EDGAR2Form 8-K - Current report
14/6/202413:00GLOBETScan Therapeutics Announces Updates to its Board of..
30/5/202413:00GLOBETScan Therapeutics Announces Upcoming Presentation at the..
29/5/202413:00GLOBETScan Therapeutics Receives FDA’s Regenerative Medicine..
13/5/202413:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/5/202413:15EDGAR2Form 8-K - Current report
13/5/202413:00GLOBETScan Therapeutics Reports First Quarter 2024 Financial..
09/5/202413:00GLOBETScan Therapeutics Announces First Patient Dosed in Phase 1..
24/4/202422:05GLOBETScan Therapeutics Announces Upcoming Presentations at the..
24/4/202417:03GLOBETScan Therapeutics Announces Exercise of Underwriters'..
22/4/202423:01GLOBETScan Therapeutics Announces Upcoming Presentations at the..
19/4/202416:05GLOBETScan Therapeutics Announces Closing of Upsized Public..
17/4/202406:30GLOBETScan Therapeutics Announces Pricing of Upsized $150 Million..
16/4/202422:25GLOBETScan Therapeutics Announces Launch of $125 Million Proposed..
16/4/202422:01GLOBETScan Therapeutics Provides Clinical Pipeline Update and..
08/4/202414:00GLOBETScan Therapeutics Appoints Seasoned Hematology and Oncology..
02/4/202413:00GLOBETScan Therapeutics Announces Upcoming Presentation at the..
06/3/202422:11EDGAR2Form S-3 - Registration statement under Securities Act of..
06/3/202422:05EDGAR2Form S-8 - Securities to be offered to employees in employee..
06/3/202413:30EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
06/3/202413:15EDGAR2Form 8-K - Current report
14/2/202422:45EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
29/1/202413:15EDGAR2Form 8-K - Current report
Apertura: 2,91 Min: 2,87 Max: 3,05
Chiusura: 2,93

La tua Cronologia

NASDAQ
TCRX
TScan Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network